Dr. Nicholas Robert, M.D

NPI: 1992772925
Total Payments
$34,071
2023 Payments
$7,180
Companies
8
Transactions
64

Payment Breakdown by Category

Consulting$18,430 (54.1%)
Research$10,740 (31.5%)
Travel$3,509 (10.3%)
Food & Beverage$1,384 (4.1%)
Education$7.48 (0.0%)

Payments by Nature

Nature of Payment Amount Transactions Share
Consulting Fee $18,430 6 54.1%
Unspecified $10,740 19 31.5%
Travel and Lodging $3,509 13 10.3%
Food and Beverage $1,384 24 4.1%
Education $7.48 2 0.0%

Payments by Type

General
$23,331
45 transactions
Research
$10,740
19 transactions

Top Paying Companies

Company Total Records Latest Year
E.R. Squibb & Sons, L.L.C. $17,178 33 $0 (2019)
PFIZER INC. $7,510 4 $0 (2023)
Boehringer Ingelheim Pharmaceuticals, Inc. $5,908 9 $0 (2018)
Regeneron Pharmaceuticals, Inc. $2,976 14 $0 (2020)
NOVARTIS PHARMACEUTICALS CORPORATION $254.67 1 $0 (2018)
Seagen Inc. $132.12 1 $0 (2022)
AstraZeneca Pharmaceuticals LP $100.30 1 $0 (2017)
Janssen Biotech, Inc. $13.09 1 $0 (2018)

Payment History by Year

Year Amount Transactions Top Company
2023 $7,180 3 PFIZER INC. ($7,180)
2022 $462.12 2 PFIZER INC. ($330.00)
2020 $2,023 6 Regeneron Pharmaceuticals, Inc. ($2,023)
2019 $1,815 9 Regeneron Pharmaceuticals, Inc. ($952.81)
2018 $10,056 20 Boehringer Ingelheim Pharmaceuticals, Inc. ($5,908)
2017 $12,535 24 E.R. Squibb & Sons, L.L.C. ($12,435)

All Payment Transactions

64 individual payment records from CMS Open Payments — Page 2 of 3

Date Company Product Nature Form Amount Type
09/28/2018 Boehringer Ingelheim Pharmaceuticals, Inc. GILOTRIF (Drug) Food and Beverage In-kind items and services $125.00 General
Category: ONCOLOGY
09/28/2018 Boehringer Ingelheim Pharmaceuticals, Inc. GILOTRIF (Drug) Food and Beverage In-kind items and services $60.81 General
Category: ONCOLOGY
09/28/2018 Boehringer Ingelheim Pharmaceuticals, Inc. GILOTRIF (Drug) Food and Beverage In-kind items and services $31.75 General
Category: ONCOLOGY
09/28/2018 Boehringer Ingelheim Pharmaceuticals, Inc. GILOTRIF (Drug) Food and Beverage In-kind items and services $21.27 General
Category: ONCOLOGY
07/17/2018 E.R. Squibb & Sons, L.L.C. OPDIVO (Biological) Consulting Fee Cash or cash equivalent $575.00 General
Category: Oncology
04/23/2018 E.R. Squibb & Sons, L.L.C. Consulting Fee Cash or cash equivalent $2,300.00 General
04/10/2018 E.R. Squibb & Sons, L.L.C. Travel and Lodging Cash or cash equivalent $45.32 General
04/04/2018 Janssen Biotech, Inc. Erleada (Drug), DARZALEX Food and Beverage In-kind items and services $13.09 General
Category: Oncology
03/23/2018 E.R. Squibb & Sons, L.L.C. Food and Beverage Cash or cash equivalent $100.91 General
03/23/2018 E.R. Squibb & Sons, L.L.C. Food and Beverage Cash or cash equivalent $75.67 General
03/23/2018 E.R. Squibb & Sons, L.L.C. Food and Beverage Cash or cash equivalent $48.39 General
03/22/2018 E.R. Squibb & Sons, L.L.C. Travel and Lodging Cash or cash equivalent $363.77 General
03/22/2018 E.R. Squibb & Sons, L.L.C. Travel and Lodging Cash or cash equivalent $246.38 General
03/22/2018 E.R. Squibb & Sons, L.L.C. Food and Beverage Cash or cash equivalent $125.00 General
02/12/2018 NOVARTIS PHARMACEUTICALS CORPORATION MEKINIST (Drug) In-kind items and services $254.67 Research
Study: RESEARCH RELATED PUBLICATION SUPPORT • Category: ONCOLOGY
11/24/2017 E.R. Squibb & Sons, L.L.C. Consulting Fee Cash or cash equivalent $5,175.00 General
11/21/2017 E.R. Squibb & Sons, L.L.C. Travel and Lodging Cash or cash equivalent $21.92 General
10/06/2017 E.R. Squibb & Sons, L.L.C. Food and Beverage Cash or cash equivalent $56.44 General
10/06/2017 E.R. Squibb & Sons, L.L.C. Food and Beverage Cash or cash equivalent $30.97 General
10/06/2017 E.R. Squibb & Sons, L.L.C. Food and Beverage Cash or cash equivalent $19.59 General
10/06/2017 E.R. Squibb & Sons, L.L.C. Food and Beverage Cash or cash equivalent $17.99 General
10/06/2017 E.R. Squibb & Sons, L.L.C. Food and Beverage Cash or cash equivalent $9.41 General
10/05/2017 E.R. Squibb & Sons, L.L.C. Travel and Lodging Cash or cash equivalent $713.34 General
10/05/2017 E.R. Squibb & Sons, L.L.C. Travel and Lodging Cash or cash equivalent $262.78 General
10/05/2017 E.R. Squibb & Sons, L.L.C. Education Cash or cash equivalent $3.64 General

Research Studies & Clinical Trials

Study Name Company Amount Records
PALBOCICLIB CLINICAL PUBLICATION PROGRAM PFIZER INC. $7,510 4
LIBTAYO CLINICAL PUBLICATION PROGRAM Regeneron Pharmaceuticals, Inc. $2,023 6
Libtayo Clinical Publication Program Regeneron Pharmaceuticals, Inc. $952.81 8
RESEARCH RELATED PUBLICATION SUPPORT NOVARTIS PHARMACEUTICALS CORPORATION $254.67 1

About Dr. Nicholas Robert, M.D

Dr. Nicholas Robert, M.D is a Hematology & Oncology healthcare provider based in Fairfax, Virginia. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 03/08/2006. The National Provider Identifier (NPI) number assigned to this provider is 1992772925.

According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Nicholas Robert, M.D has received a total of $34,071 in payments from pharmaceutical and medical device companies, with $7,180 received in 2023. These payments were reported across 64 transactions from 8 companies. The most common payment nature is "Consulting Fee" ($18,430).

Practice Information

  • Specialty Hematology & Oncology
  • Location Fairfax, VA
  • Active Since 03/08/2006
  • Last Updated 12/13/2011
  • Taxonomy Code 207RH0003X
  • Entity Type Individual
  • NPI Number 1992772925

Products in Payments

  • IBRANCE (Drug) $3,200
  • LIBTAYO (Biological) $2,976
  • GILOTRIF (Drug) $1,103
  • OPDIVO (Biological) $575.00
  • MEKINIST (Drug) $254.67
  • Erleada (Drug) $13.09

Data Sources

Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.

Hematology & Oncology Doctors in Fairfax